Brief: Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052
23/06/2025 12:04
June 23 (Reuters) - Aclaris Therapeutics Inc ACRS.O: ACLARIS THERAPEUTICS INITIATES PHASE 1A/1B PROGRAM FOR ITS NOVEL BISPECIFIC ANTIBODY ATI-052 ACLARIS THERAPEUTICS INC - PHASE 1A RESULTS EXPECTED EARLY 2026, PHASE 1B RESULTS IN H2 2026 Source text: ID:nGNX4hSPsB Further company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Aclaris Therapeutics Q3 revenue beats analyst estimates
Brief: Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aclaris Therapeutics Q2 revenue beats analyst estimates